HIF1α inhibition by dual targeting of CDK4/6 and HSP90 reduces cancer cell viability including Rb-deficient cells
Zhao, S.; Zhou, L.; Dicker, D.; Lev, A.; Zhang, S.; El-Deiry, W.
Show abstract
Most cancers harbor intra-tumoral hypoxia which promotes tumor progression and therapy resistance. Hypoxia-inducible factor 1 (HIF1) mediates an adaptive response to hypoxia and contributes to multiple cancer hallmarks. We describe cancer therapeutic targeting of HIF1 by combination of CDK4/6 inhibitors (CDK4/6i) and heat-shock protein 90 inhibitors (HSP90i). CDK1 contributes to HSP90-mediated HIF1 stabilization whereas CDK1-knockdown enhances HIF1 reduction by HSP90i. Dual CDK1- and HSP90-inhibition increases apoptosis and synergistically inhibits cancer cell viability. To translate our findings, we use FDA-approved CDK4/6i in combination with HSP90i to reduce HIF1 expression and suppress viability of multiple cancer cell types, including Rb-deficient cancer cells. Overexpression of HIF1668E partially rescues the cell viability inhibition by combination CDK4/6i and HSP90i treatment under hypoxia. CDK4/6i and HSP90i suppresses tumor growth in vivo. Thus, combined targeting of CDK4/6 and HSP90, through a drug class effect, inhibits HIF1 and shows preclinical anti-cancer therapeutic efficacy, including with Rb-deficiency.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma 95%
- A novel ALDH1A1 inhibitor blocks platinum-induced senescence and stemness in ovarian cancer 94%
- Histone deacetylase inhibitor induces acetyl-CoA depletion leading to lethal metabolic stress in RAS-pathway activated cells 94%
Similar papers in this journal
- Selective Impact of ALK and MELK Inhibition on ERα Stability and Cell Proliferation in Cell Lines Representing Distinct Molecular Phenotypes of Breast Cancer 95%
- MDM2 inhibitors, nutlin-3a and navtemadelin, retain efficacy in human and mouse cancer cells cultured in hypoxia 95%
- Epithelial-mesenchymal transition sensitizes breast cancer cells to cell death via the fungus-derived sesterterpenoid ophiobolin A 95%
Similar papers in this journal
- CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis 95%
- DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma 94%
- EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition 94%
Similar papers in this journal
- Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death 95%
- Clinical positioning of the IAP antagonist tolinapant (ASTX660) in colorectal cancer 95%
- Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers 95%